Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$89.18
+1.8%
$91.92
$81.04
$134.63
$225.27B0.3511.01 million shs12.39 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$69.46
-1.9%
$80.07
$58.10
$121.06
$8.94B1.02976,795 shs660,934 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.20
+0.8%
$26.06
$24.48
$31.54
$142.93B0.6138.88 million shs32.32 million shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.56%-3.31%-9.34%-32.41%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-6.96%-4.88%-15.28%+1.68%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-3.83%-4.65%-4.61%-9.19%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.35.05.03.92.83.33.8
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.0634 of 5 stars
3.50.00.00.04.12.50.0
Pfizer Inc. stock logo
PFE
Pfizer
4.9866 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1231.33% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.00
Buy$147.50112.35% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9226.67% Upside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$160.00 ➝ $160.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/26/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$160.00 ➝ $160.00
2/26/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $140.00
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
2/11/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.51$3.09 per share28.82$14.85 per share6.01
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$13.04 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.25$3.95 per share6.38$15.81 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7313.259.010.7726.67%45.35%17.36%4/24/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.878.320.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest PCVX, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
2/25/2025Q4 2024
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.16-$1.02+$0.14-$1.02N/AN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.63%+5.73%48.14%14 Years
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.83%+2.50%121.99%16 Years

Latest PCVX, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.88
17.88
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160128.76 million120.77 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. stock logo
Bcwm LLC Invests $4.26 Million in Pfizer Inc. (NYSE:PFE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$89.18 +1.58 (+1.80%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$89.15 -0.03 (-0.03%)
As of 03/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$69.46 -1.31 (-1.85%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$69.44 -0.02 (-0.03%)
As of 03/28/2025 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer stock logo

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$25.14 -0.07 (-0.26%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.